Choose the right Module 1 correspondence task

How do you choose the correct Module 1 correspondence task?

Identify the application, lifecycle stage, requested action, relevant facts and intended recipient before choosing a heading. Separate advice, permission, notification and supporting statements, then use the task’s governing source and delivery instructions. Module 1.12 organizes different correspondence purposes; it does not give them common eligibility criteria or make a submitted letter an agency decision.

Before you begin

FDA Module 1.12 correspondence family; actual obligations and delivery routes depend on the task.

What you will prepare: A classified request with a named owner, governing source and appropriate preparation guide.

Write a one-line transaction description

Before selecting a template, write: who is asking which FDA office to do what, for which product/application, at which lifecycle stage, and on what evidence? An unqualified request for a “waiver,” “exception” or “designation” is undetermined until those inputs are resolved.

The family contains different tasks: development advice; permission to charge; a waiver of a specified regulatory requirement; planned emergency research; study discontinuation; generic-application statements; environmental material; quality-defect alerts; and designations. These share electronic organization, not eligibility or review standards.

Use the consequence to select the next task

For development advice, prepare the focused question and relevant existing evidence; formal meeting requests and packages have the neighboring 1.6 family. For charging, establish clinical trial versus expanded access before preparing the cost rationale. For a waiver, identify the exact provision and any more specific heading such as pediatric or bioavailability relief.

For emergency research, the EFIC guide covers protocol justification, public disclosure and related correspondence; it is not a single-patient emergency treatment shortcut. For a discontinued study, distinguish protocol closure from withdrawal of the entire IND. For an ANDA, prepare the basis statement separately from the generic/RLD comparison and the GDEA factual review.

For a distributed-product quality issue, assess the FAR clock immediately rather than waiting for an ordinary correspondence sequence. Orphan designation has an OOPD submission route, while an RMAT request accompanies an initial IND or amendment. A heading in the application does not replace the responsible program's actual delivery procedure.

Give the author a usable preparation record

Create a short record with the chosen task, reason, governing source, due-date basis, evidence owners, signer/reviewer and intended recipient. Record applicability as applies, conditional, not applicable or undetermined with a reason. Keep drafting status separate: a required document can still be missing, and a completed letter can still be inapplicable.

Fictional editorial exercise: a request arrives to “waive the study.” Ask whether it is pediatric evidence, in-vivo bioequivalence, a specific IND requirement or another task. Continue collecting the study and application identifiers, but do not select legal grounds until the purpose is known. A template that makes the wrong question look finished is not a useful output.

Route the request with a short decision record

Complete this internal record before assigning the writing task. A missing classification should remain unresolved rather than being filled by the most familiar template.

Ambiguity exercise: the assignment says “request an exception for the study.” That could concern a regulatory requirement, a pediatric assessment, bioequivalence evidence or planned emergency research. Collect the protocol and application identifiers, the ordinary requirement and the proposed departure. Those facts are useful regardless of the eventual route. Do not select legal grounds from the word “exception” alone.

For IND advice, define a proposal and question. For charging, distinguish the clinical-trial request from expanded-access charging. For regulatory waivers, name the precise provision. For study discontinuation, establish what stopped and what continues.

Treat urgent product-quality information as a timing assessment first. The marketed-product reporting rule has a specific field-alert obligation; an ordinary correspondence workflow should not delay assessment by the responsible quality and regulatory owners. Likewise, a charging request remains a request until the required prior written authorization is obtained. A complete document and a completed regulatory action are different milestones.

Finish the handoff with the evidence owners, unresolved questions and reviewer. Use three separate statuses: whether the task applies, whether the package is ready and whether FDA has made the requested decision. That prevents a well-written but inapplicable letter, or a transmitted but ungranted request, from appearing finished.

Frequently asked questions

Sources and revisions

Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.

Related guides